K-bio emerges as global rule-setter, shedding passive role in technology exports

Hanmi Pharm leads global obesity treatment paradigm with 3.5 trillion won drug export; SK Biopharm acquires late-stage epilepsy candidate for 1.1 trillion won to build multi-drug model; Samsung Biologics seals 2.7 trillion won Swiss M&A with 3 trillion won rights offering

A technology export worth 3 trillion won ($2.17 billion) by Hanmi Pharm. A 1.1 trillion won acquisition of a drug candidate by SK Biopharm. A 2.7 trillion won merger and acquisition by Samsung Biologics.

These blockbuster deals, announced in rapid succession by South Korea's pharmaceutical and biotech industry, have sent a clear signal to the world: K-bio is no longer a peripheral follower or a simple contract research base. With cumulative technology exports this year approaching 16 trillion won, the industry's explosive growth in both scale and quality marks a decisive turning point — proof that Korean biotech has fully evolved into a "global rule-setter" that shapes the terms of competition on the world stage.

The most striking shift is a reversal of power within the global pharmaceutical ecosystem. The typical K-bio success formula had long been to out-license early-stage compounds discovered domestically to multinational drugmakers, leaving development and commercialization to overseas partners. SK Biopharm's move runs in the opposite direction: the company paid 1.1 trillion won to acquire worldwide exclusive rights to Orfakalim, a late-stage Phase 2/3 epilepsy drug candidate, and the Kv7 discovery platform from Biohaeven, a company listed on the New York Stock Exchange. A Korean pharmaceutical company has now fully established itself as a buyer capable of identifying and acquiring near-commercial assets directly in the global market.

The leap was made possible by the global infrastructure SK Biopharm had already built. Through Xcopri, its epilepsy brand drug that ranks No. 1 in the United States, the company has assembled a dedicated local direct-sales network of about 150 representatives. By immediately loading a second product onto that network to maximize marketing synergies, SK Biopharm has broken the constraints of a single-product company and completed a multinational-style business model in which it sells multiple innovative drugs directly.

The quality of drug R&D has also advanced beyond imitation to the first-in-class level — setting new standards rather than following them. Hanmi Pharm's technology export of HM17321 to Genentech, a subsidiary of the Roche Group, for up to $2.3 billion exemplifies this shift. The compound's novel non-incretin mechanism, based on a UCN2 analogue, simultaneously induces weight loss and preserves muscle mass — overcoming the chronic limitation of existing GLP-1 therapies, which tend to cause muscle loss. That unmet need was precisely what global big pharma had been most eager to address. The scientific mechanism designed by a Korean biotech has effectively been recognized as the new benchmark for the global obesity treatment paradigm.

This drug development competitiveness is borne out by record-breaking technology export figures this year. According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, domestic pharmaceutical and biotech companies have completed 12 technology export deals this year, with the nine deals whose contract values have been disclosed totaling more than 15.9 trillion won. The industry has moved away from out-licensing early preclinical compounds, shifting toward exports centered on clinically validated pipelines and platform technologies — a change that has made contract terms, including non-refundable upfront payments, dramatically more favorable than in the past.

Samsung Biologics Plant 4. [Samsung Biologics]

Backed by trillion-won capital, Korean companies have also moved into high gear on acquiring global production bases and next-generation treatment modalities in a single stroke. Samsung Biologics approved a 3 trillion won rights offering to finalize, by year-end, its 100 percent acquisition of Switzerland's Polypeptide Group — announced in July for 1.46 billion Swiss francs (about 2.7 trillion won), the largest biotech M&A in South Korean history.

Spun off from Ferring in 1996, Polypeptide Group is a leading global peptide contract development and manufacturing organization with more than 1,000 development and production projects to its name, eco-friendly solvent-reduction process technology, and a specialized workforce of about 1,500. Through the acquisition, Samsung Biologics expands its portfolio beyond antibodies, mRNA and antibody-drug conjugates to include peptides — the key ingredient in obesity and diabetes drugs, a market projected to reach 200 trillion won by 2035. The deal also gives Samsung Biologics immediate access to six production sites across five countries: Sweden, Belgium, France, the United States (Torrance and San Diego) and India. A scale-up of its second bio campus in Songdo — backed by 294.8 billion won in facility investment — will push its total production capacity to a world-leading 1.385 million liters, widening the gap over rivals. The company also kept the rights-offering ratio as low as 4.9 percent to minimize shareholder dilution, demonstrating a level of capital-market maturity to match its industrial ambitions.

The advances by Korean companies are supported by global clinical data as well. According to recent analysis by Clinical Trials Arena, a global clinical trial strategy publication, and market research firm GlobalData, first-in-class candidates account for 36 percent of South Korea's drug pipeline. A combination of factors — precision medical data drawn from a single national health insurance system covering 97 percent of the population, a fast-moving regulatory environment, and government support including a 1 trillion won biotech fund — has propelled South Korea beyond the Asia-Pacific region to emerge as a global hub for new drug innovation.

silverpaper@heraldcorp.com